Clade Therapeutics Revenue and Competitors

Location

$87M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Clade Therapeutics's estimated annual revenue is currently $12.7M per year.(i)
  • Clade Therapeutics's estimated revenue per employee is $155,000
  • Clade Therapeutics's total funding is $87M.

Employee Data

  • Clade Therapeutics has 82 Employees.(i)
  • Clade Therapeutics grew their employee count by 49% last year.

Clade Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
President / CBO, Co-FounderReveal Email/Phone
3
Co-Founder And COOReveal Email/Phone
4
Head Computational BiologyReveal Email/Phone
5
VP FinanceReveal Email/Phone
6
Associate Director, Quality AssuranceReveal Email/Phone
7
Associate Director, Molecular ImmunologyReveal Email/Phone
8
Executive Director, Head Cell EngineeringReveal Email/Phone
9
Director, Head T Cell PlatformReveal Email/Phone
10
Chief Technology OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Clade Therapeutics?

Clade Therapeutics is a seed-stage cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located at Kendall Square’s LaunchLabs, was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

keywords:N/A

$87M

Total Funding

82

Number of Employees

$12.7M

Revenue (est)

49%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.9M82-44%$19.5M
#2
$12.7M82-41%N/A
#3
$12.7M8232%$283M
#4
$11.9M82N/AN/A
#5
$22.1M8219%$25.6M